New Delhi, 28/1: The India-EU trade deal is expected to transform healthcare access in India, especially for high-cost specialty drugs and biologics.
The deal will significantly bring down the cost of advanced therapies for Indian patients.
In the short-term, a mild price reduction of 10-20 per cent will happen, but the real impact will unfold over the next 2-3 years, with prices potentially dropping by 40-70 per cent once local manufacturing scales up, biosimilars enter the market
